177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.tps5109
Abstract: TPS5109 Background: The cell surface glycoprotein prostate-specific membrane antigen (PSMA) has proven to be an ideal therapeutic target in prostate cancer (PC) as it is highly expressed by malignant prostate cells.1,2 177Lu-DOTA-HuJ591-CHO (TLX591) is a… read more here.
Keywords: biodistribution dosimetry; tlx591; safety; 177lu dota ... See more keywords